Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylamine SCHEMBL27794790 | 0.94 | CYP2D6 (0.38) | HPGDCYP1A2CYP2D6EPHX1ACLY | |
| SCHEMBL528248 | 0.88 | CYP1A2 (0.47) | HPGDCYP1A2EPHX1ACLYACACB | |
| SCHEMBL4922045 | 0.82 | CNR2 (0.33) | HPGDACLYACACBACACA | |
| SCHEMBL4922039 | 0.82 | CNR2 (0.33) | HPGDACLYACACBACACA | |
| SCHEMBL4922035 | 0.82 | CNR2 (0.33) | HPGDACLYACACBACACA | |
| SCHEMBL27796569 | 0.82 | GABRA5 (0.47) | ACLYACACBACACA | |
| SCHEMBL25826250 | 0.81 | GRM2 (0.46) | HPGDCYP1A2CYP2D6EPHX1GRM2 | |
| SCHEMBL4141844 | 0.81 | GRM2 (0.46) | HPGDCYP1A2CYP2D6EPHX1GRM2 | |
| SCHEMBL27620522 | 0.80 | GGT1 (0.46) | HPGDCYP1A2CYP2D6EPHX1GRM2 | |
| SCHEMBL1682650 | 0.78 | GRM2 (0.43) | HPGDCYP1A2CYP2D6EPHX1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248762-A1 | Malodor counteractant compositions | MCGEE THOMAS (US) | 2004-12-09 | — | — | US | claimed |
| EP-1345883-A1 | MALODOR COUNTERACTANT COMPOSITIONS | Givaudan SA (CH) | 2003-09-24 | — | — | EP | claimed |
| US-20030008787-A1 | Malodor counteractant compositions | GIVAUDAN SA | 2003-01-09 | — | — | US | claimed |
| WO-2002051788-A1 | MALODOR COUNTERACTANT COMPOSITIONS | GIVAUDAN SA (CH) | 2002-07-04 | — | — | WO | claimed |
| US-9145570-B2 | Enzymatic acylation method using an acylphosphonate donor | PCAS BIOSOLUTION (FR) | 2015-09-29 | — | — | US | disclosed |
| EP-2598644-A1 | ENZYMATIC ACYLATION METHOD USING AN ACYLPHOSPHONATE DONOR | PCAS Biosolution (FR) | 2013-06-05 | — | — | EP | disclosed |
| US-20130130337-A1 | Enzymatic Acylation Method Using an Acylphosphonate Donor | PCAS BIOSOLUTION (FR) | 2013-05-23 | — | — | US | disclosed |
| WO-2012013765-A1 | ENZYMATIC ACYLATION METHOD USING AN ACYLPHOSPHONATE DONOR | PCAS BIOSOLUTION (FR) | 2012-02-02 | — | — | WO | disclosed |
| EP-1345883-B1 | MALODOR COUNTERACTANT COMPOSITIONS | GIVAUDAN SA (CH) | 2010-02-17 | — | — | EP | disclosed |
| US-7332462-B2 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7288507-B2 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20070116655-A1 | MALODOR COUNTERACTANT COMPOUNDS | GIVAUDAN SA (CH) | 2007-05-24 | — | — | US | disclosed |
| US-20060034789-A1 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2006-02-16 | — | — | US | disclosed |
| US-20040248762-A1 | Malodor counteractant compositions | MCGEE THOMAS (US) | 2004-12-09 | — | — | US | disclosed |
| EP-1345883-A1 | MALODOR COUNTERACTANT COMPOSITIONS | Givaudan SA (CH) | 2003-09-24 | — | — | EP | disclosed |
| US-6610648-B2 | Alkyl 3-phenylprop-2-enoic acid ester derivatives | GIVAUDAN SA (CH) | 2003-08-26 | — | — | US | disclosed |
| US-20030008787-A1 | Malodor counteractant compositions | GIVAUDAN SA | 2003-01-09 | — | — | US | disclosed |
| WO-2002051788-A1 | MALODOR COUNTERACTANT COMPOSITIONS | GIVAUDAN SA (CH) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248762-A1 | Malodor counteractant compositions | MAL2, OPRM1, OR51E2 | HPGD 3617/4885CYP1A2 964/4885CYP2D6 1487/4885 |
| US-20060034789-A1 | Malodor counteractant compounds | MAL2, OR51E2, OPRM1 | HPGD 3591/4885CYP1A2 576/4885CYP2D6 1089/4885 |
| US-20070116655-A1 | MALODOR COUNTERACTANT COMPOUNDS | MAL2, OR51E2, OPRM1 | HPGD 3681/4885CYP1A2 666/4885CYP2D6 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.